U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07838766) titled 'Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care' on Sept. 18.
Brief Summary: Heart failure is a complex clinical syndrome with high hospitalization rates and high mortality risks. While NT-proBNP is widely used in clinical practice to assist in diagnosis and assessment, its ability to detect prognosis in heart failure remains insufficient. Recent scientific research has found that phenylalanine in the blood and its endogenous toxic substance phenylpyruvate are closely related to impaired energy synthesis in heart muscle cells, making them highly promising next-generation ...